China Biopharmaceutical (01177): Marketing application for TQH2722 injection "IL-4R monoclonal antibody" accepted

Zhito Finance APP News: Sino Biopharmaceutical (01177) has announced that the National Class 1 innovative drug TQH2722 injection "IL-4R monoclonal antibody," independently developed by the Company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has submitted a new drug application to the Center for Drug Evaluation (CDE) of China's National Medical Products Administration and has been accepted, for the treatment of moderate-to-severe atopic dermatitis (AD) in adults whose condition is inadequately controlled with topical treatments or who are unsuitable for topical treatment.